MET and adenocarcinoma: Finally, MET dysregulation can occur via gene mutation, most notably the MET exon 14 skipping mutation seen in about 3–4% of adenocarcinoma and 2% of squamous cell carcinoma but in higher frequencies in adenosquamous carcinoma (6%) and pulmonary sarcomatoid carcinoma (9–22%) [15,18].